Xencor (XNCR) Change in Accured Expenses (2013 - 2026)
Xencor's (XNCR) quarterly Change in Accured Expenses came in at -$707000.0 in Q1 2026, up 77.58% year-on-year from -$398121.4 in Q1 2025, and down 110.18% on a QoQ basis from $6.9 million in Q4 2025.
Xencor (XNCR) Change in Accured Expenses (2013 - 2026) Analysis & Trends
Xencor (XNCR) has 14 years of Change in Accured Expenses data on file, last reported at -$707000.0 in Q1 2026.
- On a quarterly basis, Change in Accured Expenses rose 77.58% year-over-year to -$707000.0 in Q1 2026; TTM through Mar 2026 was $16.2 million, a 531.53% increase from a year earlier, with the FY2025 full-year figure at $13.8 million, up 417.37% from the prior year.
- Change in Accured Expenses for Q1 2026 stood at -$707000.0, down from $6.9 million in the prior quarter.
- Over the last five years, Change in Accured Expenses for XNCR reached as high as $6.9 million in Q4 2025 and fell as low as -$10.1 million in Q1 2024.
- Historically, Change in Accured Expenses has averaged $756647.1 across 5 years, with a median of $2.9 million in 2022.
- Across the five-year window, Change in Accured Expenses sank 581.72% in 2024 and surged 212.15% in 2025, its largest moves.
- Year by year, Change in Accured Expenses stood at -$561000.0 in 2022, then tumbled by 61.85% to -$908000.0 in 2023, then sank by 581.72% to -$6.2 million in 2024, then jumped by 212.15% to $6.9 million in 2025, then tumbled by 110.18% to -$707000.0 in 2026.
- Per Business Quant data, the three most recent Change in Accured Expenses figures were -$707000.0 in Q1 2026, $6.9 million in Q4 2025, and $4.2 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 1.13 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 931,000.00 |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | -16.82 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 23.10 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 107.70 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -16.74 Mn |
| 10 | Xencor | 1.49 Bn | 1.11 Bn | - | -707,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -707,000.00 |
| Mar 31, 2026 | -707,000.00 |
| Dec 31, 2025 | 6.94 Mn |
| Dec 31, 2025 | 6.94 Mn |
| Sep 30, 2025 | 4.22 Mn |
| Sep 30, 2025 | 4.22 Mn |
| Jun 30, 2025 | 5.79 Mn |
| Jun 30, 2025 | 5.79 Mn |
| Mar 31, 2025 | -3.15 Mn |
| Mar 31, 2025 | -3.15 Mn |
| Dec 31, 2024 | -6.19 Mn |
| Dec 31, 2024 | -6.19 Mn |
| Sep 30, 2024 | 5.85 Mn |
| Sep 30, 2024 | 5.85 Mn |
| Jun 30, 2024 | 6.07 Mn |
| Jun 30, 2024 | 6.07 Mn |
| Mar 31, 2024 | -10.07 Mn |
| Mar 31, 2024 | -10.07 Mn |
| Dec 31, 2023 | -908,000.00 |
| Dec 31, 2023 | -908,000.00 |